Efficacy of oral alendronate in children with osteogenesis imperfecta.
The purpose of this study was to investigate the efficacy of oral alendronate for children with osteogenesis imperfecta. Nine boys and seven girls of average age 9.5 years were given oral alendronate for an average of 4 years. Fracture frequency decreased, and in more than half of the patients the ambulatory/mobility status improved. Bone mineral density improved significantly, and restoration of collapsed vertebral bodies was observed. Urinary excretion of calcium and a bone resorption marker decreased significantly. Iliac crest physis biopsy showed an expanded primary spongiosa area with numerous multinucleated cells. This study reveals that oral alendronate caused biochemical, radiologic, and histologic changes along with clinical improvement. Oral alendronate treatment, which is convenient for the school-age group, was found to be a tolerable and efficacious treatment for children with moderate or severe osteogenesis imperfecta.
Cho
Tae-Joon
TJ
Department of Orthopaedic Surgery, Seoul National University Children's Hospital, Seoul, Korea.
Choi
In Ho
IH
Chung
Chin Youb
CY
Yoo
Won Joon
WJ
Park
Moon Seok
MS
Park
Yong Koo
YK
D000284:Administration, Oral; D000293:Adolescent; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy / Q000652:urine; D002118:Calcium / Q000652:urine; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D010013:Osteogenesis Imperfecta / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011859:Radiography
D002118:Calcium; D019386:Alendronate